Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Core Insights - Aptose Biosciences Inc. is a clinical-stage precision oncology company focused on developing tuspetinib (TUS) as a frontline therapy for newly diagnosed acute myeloid leukemia (AML) [1][5] - The company will participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto on May 5-6, 2025, where Dr. William G. Rice will present and host one-on-one meetings [1][2][4] Company Overview - Aptose is committed to developing precision medicines to address unmet medical needs in oncology, with a focus on hematology [5] - The company's pipeline includes small molecule cancer therapeutics designed for single-agent efficacy and to enhance the efficacy of other anti-cancer therapies without overlapping toxicities [5] - Tuspetinib (TUS) is an oral kinase inhibitor that has shown activity as both a monotherapy and in combination therapy for patients with relapsed or refractory AML, and is being developed as a triplet therapy for newly diagnosed AML [5] Conference Details - The 2025 Bloom Burton & Co. Healthcare Investor Conference will feature corporate updates from various Canadian healthcare companies, providing opportunities for investors to engage with company representatives [4] - Dr. William G. Rice's corporate presentation is scheduled for May 5, 2025, at 3:00 p.m. EDT, and will be available via webcast [3]